Results from one such trial [65] for patients with Stage IIIB/IV non-small cell lung carcinoma (NSCLC) treated with DEX loaded with MAGE3/4/10 peptides showed the DEX vaccines were well tolerated, and some patients demonstrated minor immune responses via delayed-type hypersensitivity (DTH) analysis and in vitro assays, with more significant responses seen in natural killer (NK) cell activity. The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.